Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iloperidone
- Development stage
- Approved
- Lead developer
- Vanda Pharmaceuticals
- Modality
- Small Molecules
01
Overview
Iloperidone is a second-generation (atypical) antipsychotic of the piperidinyl-benzisoxazole class, approved for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adults. It acts primarily as an antagonist at central dopamine D2 and serotonin 5‑HT2A receptors, with additional antagonism at D3 and α1‑adrenergic receptors. It has moderate affinity for D4, 5‑HT6, and 5‑HT7 receptors, low affinity for D1, 5‑HT1A, and histamine H1 receptors, and negligible activity at muscarinic cholinergic receptors. The drug was first FDA-approved in May 2009. Its efficacy is thought to result from rebalancing dopamine and serotonin neurotransmission in the brain[2][4][7][8].
- Brand names
- FanaptFanaptumFiaptaZomaril
- Other names
- IloperidonaIlopéridoneIloperidonum
02
Targets
ADRA1A (α1A)ADRA2C (α2C)DRD2 (Dopamine D2 Receptor)DRD3 (Dopamine receptor D3)DRD4 (Dopamine D4 Receptor)HTR2A (Serotonin receptor 5-HT2A)HTR6 (5-hydroxytryptamine receptor 6)HTR7 (5-hydroxytryptamine receptor 7)
Beyond the preview
Go deeper on iloperidone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iloperidone.